BioMarin prices Vimizim at $1,068 per vial; $380k expected annual cost
This article was originally published in Scrip
Patients with a rare lysosomal storage disorder, known as Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A syndrome, will be paying $380,000 per year for BioMarin Pharmaceutical's newly approved enzyme replacement treatment (ERT) Vimizim (elosulfase alfa), company officials revealed on 18 February.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.